Expert Interview
Discussing current use of Cobenfy (KarXT) in treating patients with schizophrenia
Ticker(s): BMY, ABBVInstitution: UHS
- Board-certified clinician in both adult and child psychiatry
- Manages ~75 schizophrenia patients
- Has prescribed Cobenfy ~25 times as of April 2025
How many patients do you have on KarXT?
Added By: wilson_adminHow challenging has reimbursement been?
Added By: wilson_adminDoes you anticipate the failure of KarXT in an adjunct setting will affect your prescribing patterns at all?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
